Поиск по репозиторию
Статья
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
L. Scarfò,
T. Chatzikonstantinou,
G. Rigolin,
G. Quaresmini,
M. Motta,
C. Vitale,
J. Garcia-Marco,
J. Hernández-Rivas,
F. Mirás,
M. Baile,
J. Marquet,
C. Niemann,
G. Reda,
T. Munir,
E. Gimeno,
M. Marchetti,
F. Quaglia,
M. Varettoni,
J. Delgado,
S. Iyengar,
A. Janssens,
R. Marasca,
A. Ferrari,
C. Cuéllar-García,
G. Itchaki,
M. Špaček,
L. De Paoli,
L. Laurenti,
M. Levin,
E. Lista,
F. Mauro,
M. Šimkovič,
E. Van Der Spek,
E. Vandenberghe,
L. Trentin,
E. Wasik-Szczepanek,
R. Ruchlemer,
D. Bron,
M. De Paolis,
G. Del Poeta,
L. Farina,
M. Foglietta,
M. Gentile,
Y. Herishanu,
T. Herold,
O. Jaksic,
A. Kater,
S. Kersting,
L. Malerba,
L. Orsucci,
V. Popov,
P. Sportoletti,
M. Yassin,
B. Pocali,
G. Barna,
A. Chiarenza,
G. dos Santos,
E. Nikitin,
M. Andres,
M. Dimou,
M. Doubek,
A. Enrico,
Y. Hakobyan,
O. Kalashnikova,
M. Ortiz Pareja,
M. Papaioannou,
D. Rossi,
N. Shah,
A. Shrestha,
O. Stanca,
N. Stavroyianni,
V. Strugov,
C. Tam,
M. Zdrenghea,
M. Coscia,
K. Stamatopoulos,
G. Rossi,
A. Rambaldi,
E. Montserrat,
R. Foà,
A. Cuneo,
P. Ghia,
2020
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Цитирование
Похожие публикации
A. Dyusupova,
R. Faizova,
O. Yurkovskaya,
M. Goncharov,
M. Pisov,
A. Shevtsov,
M. Goncharov,
M. Pisov,
A. Shevtsov,
Версии
- 1. Version of Record от 2020-09-01
Метаданные
Об авторах
-
L. Scarfò
Università Vita-Salute San Raffaele -
T. Chatzikonstantinou
George Papanicolaou General Hospital -
G. Rigolin
University of Ferrara -
G. Quaresmini
Papa Giovanni XXIII Hospital -
M. Motta
Spedali Civili Di Brescia -
C. Vitale
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino -
J. Garcia-Marco
Hospital Universitario Puerta de Hierro -
J. Hernández-Rivas
Hospital Universitario Infanta Leonor -
F. Mirás
Hospital Universitario 12 de Octubre -
M. Baile
Complejo Asistencial Universitario de Salamanca -
J. Marquet
Hospital Ramon y Cajal -
C. Niemann
Rigshospitalet -
G. Reda
Ospedale Maggiore Policlinico Milano -
T. Munir
St James's University Hospital -
E. Gimeno
Hospital del Mar -
M. Marchetti
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo -
F. Quaglia
Università degli Studi di Verona -
M. Varettoni
Fondazione IRCCS Policlinico San Matteo -
J. Delgado
Hospital Clinic Barcelona -
S. Iyengar
Royal Marsden Hospital, London -
A. Janssens
KU Leuven– University Hospital Leuven -
R. Marasca
Università degli Studi di Modena e Reggio Emilia -
A. Ferrari
IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia -
C. Cuéllar-García
Consorci Sanitari Terrassa -
G. Itchaki
Tel Aviv University, Sackler Faculty of Medicine -
M. Špaček
Charles University -
L. De Paoli
Università degli Studi del Piemonte Orientale "Amedeo Avogadro" -
L. Laurenti
Policlinico Universitario Agostino Gemelli -
M. Levin
Albert Schweitzer Hospital, Dordrecht -
E. Lista
Struttura Semplice Dipartimentale di Ematologia -
F. Mauro
Sapienza Università di Roma -
M. Šimkovič
Faculty Hospital at Hradec Kralove -
E. Van Der Spek
Rijnstate Hospital -
E. Vandenberghe
Trinity College Dublin -
L. Trentin
Università degli Studi di Padova -
E. Wasik-Szczepanek
Medical University of Lublin -
R. Ruchlemer
Shaare Zedek Medical Center -
D. Bron
Institut Jules Bordet -
M. De Paolis
Ospedale Vito Fazzi -
G. Del Poeta
Università degli Studi di Roma Tor Vergata -
L. Farina
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan -
M. Foglietta
SC Ematologia - M. Gentile
-
Y. Herishanu
Tel Aviv University -
T. Herold
Klinikum der Universität München -
O. Jaksic
University of Zagreb School of Medicine -
A. Kater
Amsterdam UMC - University of Amsterdam -
S. Kersting
HagaZiekenhuis -
L. Malerba
Azienda Ospedaliera "Ospedali Riuniti Marche Nord" -
L. Orsucci
Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino -
V. Popov
Colentina Hospital -
P. Sportoletti
Università degli Studi di Perugia -
M. Yassin
National Center for Cancer Care and Research -
B. Pocali
Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli -
G. Barna
Semmelweis Egyetem -
A. Chiarenza
Università degli Studi di Catania -
G. dos Santos
Hospital de Clinicas Dr. Manuel Quintela -
E. Nikitin
S.P. Botkin Hospital -
M. Andres
University Hospital Bern -
M. Dimou
University of Athens Medical School -
M. Doubek
Středoevropský Technologický Institut, Masarykova univerzita -
A. Enrico
Instituto Universitario del Hospital Italiano de Buenos Aires -
Y. Hakobyan
Hematology Center after Prof. R.H.Yeolyan -
O. Kalashnikova
Pavlov University -
M. Ortiz Pareja
H. Carlos Haya -
M. Papaioannou
A.H.E.P.A. Hospital -
D. Rossi
Institute of Oncology Research IOR, Oncology Institute of Southern Switzerland -
N. Shah
Norfolk and Norwich University Hospitals NHS Foundation Trust -
A. Shrestha
Nepal Cancer Hospital & Research Centre -
O. Stanca
Universitatea de Medicina si Farmacie Carol Davila din Bucuresti -
N. Stavroyianni
George Papanicolaou General Hospital -
V. Strugov
Almazov National Medical Research Centre -
C. Tam
Peter Maccallum Cancer Centre -
M. Zdrenghea
Universitatea de Medicina si Farmacie Iuliu Hatieganu din Cluj-Napoca -
M. Coscia
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino -
K. Stamatopoulos
Center For Research And Technology - Hellas -
G. Rossi
Spedali Civili Di Brescia -
A. Rambaldi
Papa Giovanni XXIII Hospital -
E. Montserrat
Hospital Clinic Barcelona -
R. Foà
Sapienza Università di Roma -
A. Cuneo
University of Ferrara -
P. Ghia
Università Vita-Salute San Raffaele
Название журнала
- Leukemia
Том
- 34
Выпуск
- 9
Страницы
- 2354-2363
Финансирующая организация
- AstraZeneca
Номер гранта
- RF-2018-12368231
Тип документа
- journal article
Тип лицензии Creative Commons
- CC BY
Правовой статус документа
- Свободная лицензия
Источник
- scopus
